Holen Sie sich die Stockscreener-App
5.25
1.32%
-0.07
Handel nachbörslich:
5.23
-0.02
-0.38%
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - The Joplin Globe
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook - simplywall.st
FY2030 Earnings Forecast for Savara Issued By HC Wainwright - MarketBeat
Savara receives FDA day 74 letter for autoimmune PAP drug - Investing.com Nigeria
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara (SVRA) Advances MOLBREEVI Application with FDA and EMA - GuruFocus
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Canada
Savara Provides Regulatory Update on the MOLBREEVI* Development P - The National Law Review
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Benzinga
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVIWhat's Changed - Yahoo Finance
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA). - Bitget
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases - geneonline.com
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - MarketBeat
SVRA PE Ratio & Valuation, Is SVRA Overvalued - Intellectia AI
Assessing Savara (SVRA) Valuation After FDA Priority Review For MOLBREEVI - simplywall.st
Savara, Inc. (SVRA) Investor Outlook: An 81% Upside Potential In Rare Respiratory Disease Treatment - DirectorsTalk Interviews
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com Nigeria
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st
Savara Grants Inducement Equity Awards to New Employee - MyChesCo
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com India
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com Australia
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
Savara's Molbreevi BLA for Autoimmune Pulmonary Alveolar Proteinosis Accepted for FDA Review - marketscreener.com
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA - GuruFocus
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - The AI Journal
Chart Watch: Whats the fair value of Savara Inc stockStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach - TipRanks
GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA - MarketBeat
Major Savara Inc. (SVRA) holder reports 6.1% stake in Schedule 13G/A - Stock Titan
Savara (SVRA) Is Up 7.1% After BLA Resubmission And Pricing Reveal For Lead aPAP TherapyHas The Bull Case Changed? - simplywall.st
Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit - MarketBeat
Risk Check: Whats the fair value of Savara Inc stockQuarterly Earnings Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):